Trisomy 18 (Edwards syndrome, T18) is the second most common trisomy aneuploidy (
1). This chromosomal anomaly is characterized by multiple congenital anomalies frequently involving cardiac, respiratory, neurological, gastrointestinal, genitourinary, and skeletal malformations (
2). Congenital heart defect is detected in about 90% of patients with T18; particularly, ventricular septal defect (VSD), atrial septal defect (ASD), and patent ductus arteriosus (PDA) (
3). Furthermore, more than 50% of T18 patients are clinically associated with craniofacial abnormalities such as prominent occiput, low-set and malformed auricles, narrow bifrontal diameter, and micrognathia. In general, 10% - 50% of T18 cases showed thorax, hand, or foot anomalies; pulmonary and cardiac stenosis; renal anomaly with horseshoe defect; polycystic kidney; hydronephrosis, or double ureter. In addition, more than 50% of T18 cases had central nervous system abnormalities such as cerebellar hypoplasia, meningomyelocele, agenesis of corpus callosum, Dandy-Walker malformation, and hydrocephalus (
4). All cases had severe psychiatric and psychomotor disorders. Based on the reported literature, the prevalence of live birth in T18 cases ranges from 1/3000 to 1/10,000, with an estimated average of about 1 in 6,000 (
5-
8). Sex difference during pregnancy is identified with a 4-fold higher incidence rate in females compared to males (
9).
Most population-based studies have reported that patients with trisomy 18 do not live beyond the first year of life, and the majority of articles reported a 1-year survival rate of 10% (
1,
2,
10). Because of these poor outcomes, cardiac surgery has not been justified and is performed in a limited number of patients with T18. Provision of comfort and palliation without surgery or interventions had been accepted as the main treatment, even though patients with congenital heart disease (CHD) were expected to be normalized hemodynamically by cardiac surgery (
11). However, improvements in surgical technique and post-operative care have led to more aggressive interventions for correction of CHD, even in patients with T18. Graham et al. (
12) reported that complete repair in 35 patients with Trisomy 13 and T18 showed 90% survival at discharge. Additionally, in 2005, T18 was excluded from the list of conditions in which “resuscitation is not indicated” in the American Academy of Pediatrics neonatal resuscitation guidelines (
13). After 2005, many reports showed improved outcomes after cardiac surgery in T18 patients (
11,
14-
17). However, many pediatricians and surgeons still hesitate to perform total cardiac repair under cardiopulmonary bypass, preferring palliative surgery without cardiopulmonary bypass because the post-operative course after palliative surgery has been generally accepted as less complicated. However, there are limited data about post-operative course and survival after palliative surgery in these patients (
18,
19).